Study wrapper · #305
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
Editor's note
A 16-patient case series describing outcomes when women with overweight or obesity conceived unintentionally while using subcutaneous semaglutide and continued it into part of the first trimester. Researchers reported no major fetal anomalies among the singleton pregnancies, but the design is the point: an uncontrolled case series of this size cannot establish safety, and the absence of malformations in 16 pregnancies is only weakly reassuring given how small the number is. Notable observations include a preeclampsia rate of 18.8%, one medically indicated preterm birth at 35 weeks, and that most patients needed metformin and insulin for diabetes control after stopping semaglutide. GLP-1 receptor agonists are not established for use in pregnancy, and manufacturer labelling advises discontinuation; this report does not change that. It is best read as an early, honest description of inadvertent exposures that adds a few data points to a thin literature, with the authors themselves calling for formal safety studies. Not evidence of safety, and not guidance.
Plain-language abstract
This report describes 16 women who became pregnant unexpectedly while taking the weekly injection semaglutide and who kept using it for part of their first trimester before stopping. All were overweight or had obesity, and all had single-baby pregnancies. Doctors reviewed their medical records for how the pregnancies and babies turned out. No major birth defects were found. However, some difficulties were recorded: nearly 1 in 5 (18.8%) developed preeclampsia, a serious pregnancy blood-pressure condition; one baby was delivered early (at 35 weeks) for medical reasons; and after stopping semaglutide, most women needed other diabetes medicines (metformin and insulin) to control blood sugar. No one lost weight during pregnancy. Because this is a small collection of individual cases with no comparison group, it cannot show whether the drug is safe in pregnancy. GLP-1 medicines are not established for use during pregnancy, and the authors say proper safety studies are still needed.